The other names for semaglutide — and why each one matters

You've searched 'another name for semaglutide', here's what you're really asking

Most people arrive at this question from one of two places. Either they've seen a price or a product name online that doesn't match what their GP mentioned, or they've read about Ozempic in the news and want to know whether it's the same thing as Wegovy. Both are fair questions.

The short answer: semaglutide is the molecule. Wegovy, Ozempic and Rybelsus are three different commercial packaging arrangements of that same molecule, each carrying a different licence, a different dose schedule and a different legal use. The full semaglutide overview on this site walks through the mechanism in detail, but what follows covers the name question specifically.

Wegovy is what a prescriber reaches for when the goal is weight management. Ozempic is what a diabetes specialist or GP prescribes for blood-sugar control in type 2 diabetes. Rybelsus is Ozempic's oral equivalent, also for diabetes. Using one where the other is licensed is not a clinical shortcut, it is an off-label use that a prescriber must actively choose and justify, and MHRA guidance is clear that GLP-1 medicines should not be used for quick or cosmetic weight loss. The NHS semaglutide medicines page sets out the distinctions in plain terms, and it is worth reading if you are comparing options.

The branded names and what each one is licensed to do

Wegovy exists in two forms now. The original once-weekly injection, made by Novo Nordisk, has been available in the UK for weight management since its NICE recommendation in 2023. The maintenance dose was 2.4mg weekly, titrated slowly from 0.25mg. On 14 April 2026, the MHRA approved a dedicated single-dose 7.2mg pen, a higher maintenance option for adults with a BMI of 30 or above. Trials of the 7.2mg dose reported an average weight reduction of around 20.7% over 72 weeks, narrowing the gap with tirzepatide results. Then, on 11 June 2026, the MHRA approved a once-daily Wegovy tablet as the first oral GLP-1 medicine licensed for weight loss in the UK. If the idea of a tablet appeals, the Wegovy treatment guide covers both formats side by side.

Ozempic uses the same active ingredient but at doses calibrated for glycaemic control in type 2 diabetes: 0.25mg, 0.5mg, 1mg and 2mg weekly injections. It is not licensed for weight management in the UK. The fact that it causes weight loss as a side effect has driven significant demand, but the MHRA has been explicit about the risks of obtaining it outside diabetes care, including through sellers operating without clinical oversight.

Rybelsus is the oral tablet form of semaglutide for diabetes, in 3mg, 7mg and 14mg strengths. None of those strengths appear in the Wegovy tablet schedule, which runs 1.5mg, 4mg, 9mg and 25mg. The two oral semaglutide products are distinct medicines with distinct licences, and the tablet dose ladders must not be confused. If someone is trying to compare the two, this related page on the semaglutide naming question unpacks exactly that distinction.

Why the licence attached to the brand name actually matters

It can feel like brand names are just marketing. In medicines, they carry legal weight. The licence for a medicine determines who can be offered it, at what dose, for how long and under what monitoring conditions. NICE's recommendation for Wegovy (TA875) specifies that NHS use is within specialist weight management services, for a maximum of two years, with structured lifestyle support. No equivalent NICE appraisal governs Ozempic for weight loss, because it is not licensed for that purpose.

That distinction has real effects on what a prescriber can responsibly offer you. A clinician prescribing Ozempic for weight management is working outside the licensed indication. That does not make it automatically wrong, but it does mean the evidence base, the monitoring guidance and the manufacturer's patient safety information are not specifically designed for that use. At the cost level, there are also implications: if you have seen significantly lower prices advertised for one brand versus another, the licence difference is part of the reason, and the weight management treatment page explains the cost context for licensed weight-loss options.

One practical note worth mentioning: if you are timing a new treatment around personal logistics, such as payday or a holiday coming up, the name on the packaging matters for continuity. A prescriber who has been managing you on Wegovy cannot simply swap you to Ozempic mid-course to save money; the clinical and legal picture is different.

What this means if you are considering weight management treatment

If weight management is your goal, Wegovy is the semaglutide brand relevant to you in the UK. The once-weekly injection or the new daily tablet are both licensed routes, and the page on Wegovy's other names covers the historical naming context in more detail. Tirzepatide (Mounjaro) is a different medicine entirely (a dual-receptor agonist rather than a GLP-1 agonist alone) but comparing the two is a clinical decision for a prescriber who knows your history, not a call to make from a brand name alone.

For anyone researching the full range of semaglutide names across different markets, it is worth knowing that Wegovy and Ozempic are the UK names; international brand names differ, and our guide to other names for semaglutide covers how the same molecule is labelled in other countries. Zepbound, for example, is the US brand of tirzepatide and does not exist as a UK product.

All semaglutide products are prescription-only medicines. A prescriber's job (ours included) is to match the right licensed medicine to the right person, not to dispense whichever name someone has read about online. If you have questions about which option fits your situation, you can start a free consultation and a GPhC-registered prescriber will review your answers the same day. Questions about how treatment works in practice are also answered on our FAQs page. The clinical team page sets out who is doing the reviewing.

A useful reference: the NHS semaglutide medicines page covers all three branded products and their respective indications in plain English. For the regulatory background on the oral Wegovy approval, the MHRA's June 2026 announcement on GOV.UK is the primary source.